Milestone Medical

Milestone Medical is developing MINIject, a micro-invasive glaucoma surgery (MIGS) device delivering the soft polymer implant directly into Schlemm's canal to lower intraocular pressure — a minimally invasive approach for mild-to-moderate open-angle glaucoma. Its 47 trials span 7 Phase 1, 2 Phase 2, and 5 Phase 4 studies. Insider buying at 147 transactions is active. The MIGS segment is the fastest-growing area in glaucoma treatment; MINIject's soft biocompatible polymer design and Schlemm's canal placement offer a differentiated approach relative to current trabecular mesh devices.

<article class="bts-verified-summary" data-ticker="MIST">
<p>Milestone Medical (MIST) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for MIST were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001408443 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22MIST%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>